Pain management最新文献

{"title":"8% capsaicin patches for HIV-induced polyneuropathy: a systematic review and meta-analysis.","authors":"Brandon J Goodwin, Ankur Jain, Jessica Mitchell, Daniel Khokhar, Richard Fagbemigun, Hanna Brancaccio, Eliot Sadik, Ahmed Khawer, Akhil Chhatre","doi":"10.1080/17581869.2026.2681558","DOIUrl":"10.1080/17581869.2026.2681558","url":null,"abstract":"<p><strong>Background: </strong>Human immunodeficiency virus is a harrowing illness that causes significant sequelae besides immune suppression. One of the long-term effects of both virus and antiviral medication is distal sensory polyneuropathy. Treating this HIV-induced neuropathy is a difficult challenge for clinicians, with standard of care medications having significant side effects. Recently, 8% topical capsaicin patches have been shown to help with various other forms of neuropathy, but no systematic review has investigated the potential benefit of HIV-induced neuropathy.</p><p><strong>Methods: </strong>A thorough systematic review of five databases (PubMed, Embase, Scopus, Web of Science, Cochrane) was conducted in October 2025. Retrieved articles were screened for the primary outcome of pain scores both before and after application of the topical capsaicin patch. Statistical analysis was stepwise, with an initial heterogeneity test (Higgins I²), followed by a random-effects meta-analytics based on the moderately high degree of heterogeneity.</p><p><strong>Results: </strong>Our investigation found a total of seven articles that fit our inclusion and exclusion criteria. The overall effect size for the most common patch-application duration was d = 0.991 (95%CI: 0.619-1.36) for improvement in pain score. To control for our high heterogeneity, a leave-out analysis was conducted on the studies with highest risk of bias, with repeat meta-analytics denoting a d = 0.96.</p><p><strong>Conclusion: </strong>Our systematic review and meta-analysis notes that topical 8% capsaicin patches are effective in reducing neuropathic pain in patients with HIV-neuropathy. Future larger studies should be conducted to investigate the place of 8% capsaicin patches in the treatment algorithm for HIV-neuropathy.</p><p><strong>Protocol registration: </strong>www.crd.york.ac.uk/prospero identifier CRD420251114796.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1019-1026"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13641598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148157525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of pericapsular nerve group block combined with a lateral femoral cutaneous nerve (LFCN) block versus lumbar and sacral erector spinae plane blocks for analgesia after total hip arthroplasty: study protocol for a randomized, controlled trial with blinded outcome assessment.","authors":"Tomasz Reysner, Bahadir Ciftci, Selcuk Alver, Katarzyna Wieczorowska-Tobis, Małgorzata Reysner","doi":"10.1080/17581869.2026.2676100","DOIUrl":"10.1080/17581869.2026.2676100","url":null,"abstract":"<p><strong>Introduction: </strong>Postoperative pain after total hip arthroplasty (THA) remains a major barrier to early mobilization and recovery in older adults. Enhanced recovery pathways increasingly emphasize potentially motor-sparing regional anesthesia to ensure effective analgesia while preserving lower-limb strength and reducing opioid use.</p><p><strong>Areas covered: </strong>This prospective, randomized, controlled trial with blinded outcome assessment compares two potentially motor-sparing regional analgesic strategies in elderly patients undergoing elective THA under spinal anesthesia. Patients receive either a pericapsular nerve group block combined with a lateral femoral cutaneous nerve block or a combined lumbar and sacral erector spinae plane block, with spinal anesthesia alone as the control. The primary outcome is cumulative opioid consumption during the first 48 postoperative hours, expressed as morphine milligram equivalents. Secondary outcomes include postoperative pain intensity, quadriceps strength, time to first ambulation, and adverse events. The protocol is based on recent randomized trials, systematic reviews, and anatomical studies of potentially motor-sparing techniques for hip surgery. The trial is registered at ClinicalTrials.gov (NCT07180979).</p><p><strong>Expert opinion/commentary: </strong>This trial aims to compare the clinical profiles of targeted capsular versus segmental fascial plane approaches for postoperative analgesia in THA and to support evidence-based optimization of potentially motor-sparing regional anesthesia in elderly patients.</p><p><strong>Clinical trial registration: </strong>The www.clinicaltrials.gov identifier is NCT07180979.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"963-970"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13641620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147964628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological basis of diurnal pain fluctuations: from molecular clocks to clinical interventions.","authors":"Lutong Yue, Tao Sun","doi":"10.1080/17581869.2026.2686783","DOIUrl":"10.1080/17581869.2026.2686783","url":null,"abstract":"<p><p>Pain exhibits significant circadian rhythmic characteristics, sharing a bidirectional regulatory relationship with the biological clock. Circadian rhythm disruption has been confirmed as an important risk factor for various chronic pain conditions, severely affecting patients' pain perception and treatment response. This narrative review was informed by searches of PubMed, Web of Science, Scopus, and Google Scholar (January 2000-March 2026), supplemented by backward citation tracking.We synthesize recent advancements in molecular biology and neuroscience to elucidate the interplay between circadian rhythms and pain. Furthermore, it evaluates the clinical potential of rhythm-based intervention strategies. Emerging evidence indicates that circadian rhythms dictate pain pathogenesis by modulating core clock gene expression, endocrine signaling, and neuro-immune functions. While the diurnal patterns of pain perception are well-documented, recent studies have begun to unravel the underlying molecular mechanisms and neural circuitry. Notably, circadian misalignment exacerbates pain sensitivity and diminishes the potency of conventional analgesic treatments. Circadian biology is pivotal to modern pain management. Leveraging rhythm-based strategies offers a novel paradigm for the individualized treatment of chronic pain. This review provides a theoretical framework and practical insights for future mechanistic research and precision clinical practice.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1027-1035"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13641632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impact of nociplastic symptom burden in individuals with fibromyalgia syndrome.","authors":"Esra Akin, Ismail Saracoglu, Bilge Basakci Calik, Veli Cobankara","doi":"10.1080/17581869.2026.2723914","DOIUrl":"https://doi.org/10.1080/17581869.2026.2723914","url":null,"abstract":"<p><strong>Introduction: </strong>The clinical impact of nociplastic pain symptoms has not yet been sufficiently investigated.</p><p><strong>Purpose: </strong>The aim of this study was to examine the associations between nociplastic symptoms and pain intensity, disease severity, quality of life, and pain catastrophising in individuals with fibromyalgia (FM).</p><p><strong>Methods: </strong>This study was designed as an observational study and was conducted with 65 individuals with FM. Hypersensitivity and comorbidity symptoms were verbally assessed in individuals with FM, and the number of symptoms was recorded. Pain intensity, disease severity, quality of life, and pain catastrophizing level were assessed using clinic scales. Associations between nociplastic symptom burden and clinical outcomes were evaluated using correlation analyses, one-way ANOVA with Bonferroni post hoc tests and ANCOVA adjusted for relevant covariates.</p><p><strong>Results: </strong>Nociplastic symptoms were significantly associated with disease severity (<i>p</i> < 0.001; η²<i>p</i> = 0.256), quality of life (<i>p</i> < 0.001; η²<i>p</i> = 0.220), and pain catastrophising levels (<i>p</i> = 0.003; η²<i>p</i> = 0.162) and there were significant differences between groups in these parameters in individuals with FM.</p><p><strong>Conclusion: </strong>An increased burden of nociplastic symptoms in individuals with FM was associated with greater disease severity and higher levels of pain catastrophising, whereas quality of life was reduced.</p><p><strong>Clinical trial registration: </strong>www.clinicaltrials.gov identifier is NCT05941780.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-designing opioid stewardship guidelines for cancer pain management in Nepal: study protocol.","authors":"Sunil Shrestha, Nabin Pathak, Rajeev Shrestha, Subhas Pandit, Vibhu Paudyal, Simit Sapkota","doi":"10.1080/17581869.2026.2713525","DOIUrl":"https://doi.org/10.1080/17581869.2026.2713525","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer pain remains inadequately managed in low-resource settings such as Nepal, where regulatory barriers, stigma, limited opioid availability, and insufficient clinical training hinder effective treatment. Although opioids are essential for moderate to severe cancer pain, concerns regarding misuse and weak system-level governance restrict rational access, contributing to avoidable suffering and health inequities. The Pilot Initiative for Local Opioid Treatment (PILOT) study aims to co-design, pilot, and evaluate a contextually appropriate opioid stewardship framework to strengthen cancer pain management in Nepal.</p><p><strong>Methods: </strong>This multi-phase, participatory mixed-methods study comprises six phases. Phase I involves a systematic scoping review of opioid stewardship models in comparable low-resource settings. Phase II engages key stakeholders, including oncologists, pharmacists, nurses, palliative care providers, policymakers, patients, and caregivers, through focus group discussions (<i>n</i> = 40-50) and key informant interviews (<i>n</i> = 15-20) across urban and rural oncology settings in three provinces. Phase III is a three-round modified e-Delphi consensus process involving approximately 20-25 national and international experts, using anonymous, iterative feedback to systematically build consensus on guideline components. Phase IV convenes an in-person national guideline development workshop bringing together over 40 stakeholders to translate the consensus framework into operational recommendations. Phase V involves a 12-week pilot implementation across at least one and up to three cancer care facilities, with Kathmandu Cancer Center serving as the primary site. Primary outcomes include feasibility, acceptability, adoption, and fidelity of the stewardship guidelines. Phase VI involves iterative refinement of the guidelines based on pilot findings and preparation for national dissemination.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-11"},"PeriodicalIF":1.7,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived helpfulness of 56 treatment options in patients with chronic pain: a retrospective review.","authors":"Kian Naimi Shirazi, Lindsay G Flegge, Michelle L Miller, Amanda E Wakefield, Kylie Williams, Michael A Bushey","doi":"10.1080/17581869.2026.2718883","DOIUrl":"10.1080/17581869.2026.2718883","url":null,"abstract":"<p><strong>Background: </strong>Chronic pain affects approximately 20% of US adults and often requires multiple treatment modalities. Although many therapies are available, less is known about which treatments patients perceive as helpful in real-world settings.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed intake questionnaire data from 226 patients evaluated at a multidisciplinary pain clinic between January 2023 and March 2024. Patients rated 56 pain treatments as helpful, unhelpful, never tried, or not sure. Helpfulness was calculated as the proportion of \"helpful\" responses among patients who tried each treatment. Logistic regression models examined predictors of helpfulness for treatments with helpfulness estimates ≥50% and key covariates were conducted for the seven most helpful treatments.</p><p><strong>Results: </strong>Patients had a mean age of 45.1 ± 15.6 years, and 81.4% were female. The most frequently tried treatments were acetaminophen (90%), physical therapy (88%), and ibuprofen (83%). Treatments with helpfulness estimates ≥50% included massage therapy (77% [70%, 84%]), oxycodone (74% [65%, 82%]), psychotherapy (67% [58%, 77%]), hydromorphone (67% [54%, 79%]), physical therapy (62% [55%, 68%]), aquatic therapy (62% [50%, 73%]), and hydrocodone (61% [53%, 70%]).</p><p><strong>Conclusion: </strong>Patient-reported helpfulness varied across treatments, supporting multidisciplinary, patient-centered chronic pain care.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-9"},"PeriodicalIF":1.7,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13541267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sympathetic blocks in the treatment of erythromelalgia: case series.","authors":"Semih Gungor, Burcu Candan","doi":"10.1080/17581869.2026.2718876","DOIUrl":"https://doi.org/10.1080/17581869.2026.2718876","url":null,"abstract":"<p><strong>Background: </strong>Erythromelalgia (EM) is a rare, debilitating condition characterized by episodic burning pain, erythema, and increased skin temperature, typically affecting the distal extremities. EM significantly impairs quality of life (QoL) and may lead to functional disability. Although its pathophysiology is not fully understood, proposed mechanisms include small fiber nerve dysfunction and dysregulation of the sympathetic nervous system. Management remains challenging, with no universally effective treatment currently available.</p><p><strong>Case presentation: </strong>We present three patients with refractory lower extremity erythromelalgia treated with lumbar sympathetic block (LSB). All patients had chronic treatment-refractory symptoms and had failed multiple prior treatments, including neuropathic medications and conservative measures. Bilateral L3 LSBs were performed using a standardized approach. Two patients experienced substantial symptom improvement, with reported reductions in pain intensity and a prolonged benefit lasting several months. One patient demonstrated partial, short-term improvement. Repeated LSB procedures were performed in cases of symptom recurrence.</p><p><strong>Conclusion: </strong>In this retrospective case series, LSB was associated with symptomatic improvement in selected erythromelalgia patients, potentially by modulating sympathetic activity and regional blood flow. However, given the small sample size and retrospective design, no conclusions regarding efficacy can be drawn. Further studies are needed to better define patient selection criteria and long-term outcomes.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148796718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of intravenous ketamine for neuropathic pain: a systematic review and meta-analysis of randomized clinical trials.","authors":"Márcio José Leão Nunes Filho, Eduardo Silva Reis Barreto, Cesar Romero Antunes Júnior, Luiz Gustavo Albuquerque Mello de Oliveira, João Pedro Fernandes Gonçalves, Gabriel Teles de Oliveira Piñeiro, Clara Garrido Kraychete, Liana Maria Torres de Araujo Azi, Liliane Elze Falcão Lins-Kusterer, Durval Campos Kraychete","doi":"10.1080/17581869.2026.2714980","DOIUrl":"https://doi.org/10.1080/17581869.2026.2714980","url":null,"abstract":"<p><strong>Aim: </strong>This study evaluated the efficacy of intravenous ketamine for chronic neuropathic pain through a systematic review and meta-analysis of randomized clinical trials.</p><p><strong>Methods: </strong>Searches were conducted in PubMed, Cochrane CENTRAL, and EMBASE until March 2026 in accordance with the PRISMA framework: adult patients with chronic neuropathic pain, intravenous ketamine as the intervention, placebo as the comparator, and pain relief outcomes.</p><p><strong>Results: </strong>Fifteen randomized clinical trials (<i>n</i> = 251) were included in the systematic review, of which six trials (<i>n</i> = 135) were included in the primary outcome meta-analysis. Ketamine doses ranged from 60 µg/kg to 1 mg/kg. Pooled analysis showed that intravenous ketamine was superior to placebo in achieving a ≥50% reduction in pain intensity (RR = 2.79, 95% CI: 1.47-5.30; I² = 28.3%), with a more pronounced effect in studies using a standardized dose of 400 µg/kg (RR = 5.68; 95% CI: 2.02-15.99; I² = 0%). However, ketamine was associated with a higher incidence of adverse effects compared to placebo (RR = 3.27; 95% CI: 2.20-4.84; I² = 20.1%).</p><p><strong>Conclusion: </strong>Overall, intravenous ketamine demonstrates the potential to provide effective short-term pain relief. Although adverse events were more frequent, they were generally mild and transient. Methodological heterogeneity and small sample sizes limit the generalizability of these findings.<b>Protocol registration:</b> The www.crd.york.ac.uk/prospero identifier is CRD42021229758.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-20"},"PeriodicalIF":1.7,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148707462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcutaneous electrical nerve stimulation in the relief of primary dysmenorrhea: a systematic review and meta-analysis.","authors":"Evelin de Oliveira Wulf, Maria Rita Brandão, Mariana Olher Goveia, Juliana Cristina Frare, Humberto de Sousa Fontoura, Márcia Rosângela Buzanello, Gladson Ricardo Flor Bertolini","doi":"10.1080/17581869.2026.2714978","DOIUrl":"https://doi.org/10.1080/17581869.2026.2714978","url":null,"abstract":"<p><strong>Objective: </strong>To synthesize evidence on TENS efficacy for primary dysmenorrhea, providing quantitative meta-analysis of pain intensity, exploratory subgroup analyses on electrode placement, and systematic RoB 2 assessment, addressing gaps from previous qualitative reviews.</p><p><strong>Method: </strong>Systematic search across PubMed, VHL, Web of Science, Embase, LILACS, PEDro, and gray literature, without restrictions. RoB 2 was applied independently by two reviewers. Primary outcome: pain intensity. Meta-analysis used RevMan 5.4.1.</p><p><strong>Results: </strong>Eight studies included from 1,018 records. TENS significantly reduced pain (SMD = -1.85; 95% CI -2.90 to -0.79; <i>p</i> < 0.001), with high heterogeneity (I² = 94%). Subgroup analyses showed significant effects regardless of application site.  .</p><p><strong>Conclusion: </strong>This meta-analysis quantifies TENS analgesic effect for primary dysmenorrhea, suggesting pain reduction irrespective of electrode placement. However, very high heterogeneity, moderate-to-high risk of bias, wide parameter variability, small samples, and imprecise subgroup estimates limit certainty. TENS appears safe (no serious adverse events), but underreporting prevents firm conclusions. Standardized protocols and high-quality, low-bias trials are needed. Certainty is likely low per GRADE considerations.</p><p><strong>Protocol registration: </strong>www.crd.york.ac.uk/prospero identifier is CRD42024540314.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-16"},"PeriodicalIF":1.7,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare osteonecrosis Kienböck's disease potentially linked to COVID-19: a case report.","authors":"Hatice Ceylan","doi":"10.1080/17581869.2026.2714987","DOIUrl":"https://doi.org/10.1080/17581869.2026.2714987","url":null,"abstract":"<p><p>Kienböck's disease (KD), an avascular necrosis of the lunate bone, is a rare and progressive condition that may lead to chronic wrist pain and functional limitation. While avascular necrosis associated with COVID-19 has been reported in other skeletal sites, involvement of the lunate bone has not previously been reported. This case adds novel evidence that suggests a potential association between COVID-19 and Kienböck's disease. To demonstrate this potential association, this paper reports a case of Kienböck's disease developing following COVID-19 infection in a 50-year-old woman who was hospitalized in August 2020 with PCR-confirmed COVID-19 pneumonia and bilateral ground-glass opacities on chest CT. She had no prior corticosteroid exposure or comorbidities. Approximately 12 weeks after recovery, she developed progressive left wrist pain without any history of trauma. Subsequent imaging demonstrated avascular necrosis of the lunate bone. Interventions included autologous cytokine-rich serum injections, pharmacological pain management, and ultimately surgical lunate excision with bone grafting due to progression of the disease. This case represents the first reported instance of Kienböck's disease developing after COVID-19 infection. Increased clinician awareness may lead to earlier diagnosis and better functional outcomes.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-4"},"PeriodicalIF":1.7,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148679598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}